Division of Neurosurgery, Arthur & Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
Program in Developmental & Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Acta Neuropathol. 2012 Apr;123(4):485-499. doi: 10.1007/s00401-012-0959-7. Epub 2012 Feb 23.
Medulloblastoma comprises four distinct molecular variants: WNT, SHH, Group 3, and Group 4. We analyzed alternative splicing usage in 14 normal cerebellar samples and 103 medulloblastomas of known subgroup. Medulloblastoma samples have a statistically significant increase in alternative splicing as compared to normal fetal cerebella (2.3-times; P < 6.47E-8). Splicing patterns are distinct and specific between molecular subgroups. Unsupervised hierarchical clustering of alternative splicing events accurately assigns medulloblastomas to their correct subgroup. Subgroup-specific splicing and alternative promoter usage was most prevalent in Group 3 (19.4%) and SHH (16.2%) medulloblastomas, while observed less frequently in WNT (3.2%), and Group 4 (9.3%) tumors. Functional annotation of alternatively spliced genes reveals overrepresentation of genes important for neuronal development. Alternative splicing events in medulloblastoma may be regulated in part by the correlative expression of antisense transcripts, suggesting a possible mechanism affecting subgroup-specific alternative splicing. Our results identify additional candidate markers for medulloblastoma subgroup affiliation, further support the existence of distinct subgroups of the disease, and demonstrate an additional level of transcriptional heterogeneity between medulloblastoma subgroups.
WNT、SHH、Group 3 和 Group 4。我们分析了 14 例正常小脑样本和 103 例已知亚组的髓母细胞瘤中的选择性剪接使用情况。与正常胎儿小脑相比,髓母细胞瘤样本中的选择性剪接显著增加(2.3 倍;P < 6.47E-8)。分子亚组之间的剪接模式明显且具有特异性。选择性剪接事件的无监督层次聚类可准确地将髓母细胞瘤分配到其正确的亚组。亚组特异性剪接和替代启动子使用在 Group 3(19.4%)和 SHH(16.2%)髓母细胞瘤中最为常见,而在 WNT(3.2%)和 Group 4(9.3%)肿瘤中则较少见。选择性剪接基因的功能注释显示,与神经元发育相关的基因过表达。髓母细胞瘤中选择性剪接事件可能部分受到反义转录本的表达相关性的调节,这表明了一种可能影响亚组特异性选择性剪接的机制。我们的结果确定了髓母细胞瘤亚组归属的其他候选标志物,进一步支持了该疾病存在不同亚组的存在,并证明了髓母细胞瘤亚组之间存在额外的转录异质性。